SCHEMBL1723474

SCHEMBL1723474

CCn1cc2c(Oc3ccc(S(=O)(=O)CC)cc3)cc(C(=O)Nc3ccc(C)cn3)cc2n1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GCK P35557 18/20 0.71
KCNH2 Q12809 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723406 0.93 GCK (0.82) GCKKCNH2
SCHEMBL1728358 0.92 GCK (0.72) GCKKCNH2L3MBTL1
SCHEMBL9989543 0.84 GCK (0.67) GCKKCNH2
SCHEMBL1721832 0.84 GCK (0.77) GCKKCNH2
SCHEMBL1721928 0.83 GCK (1.00) GCKKCNH2
SCHEMBL1724533 0.83 GCK (0.86) GCKKCNH2
SCHEMBL1721828 0.82 GCK (0.59) GCK
SCHEMBL1723233 0.82 GCK (0.81) GCKKCNH2
SCHEMBL9989527 0.82 GCK (0.59) GCK
SCHEMBL9989524 0.82 GCK (0.59) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406230-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS Pfizer Inc. (US) 2012-01-18 EP claimed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US claimed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 WO claimed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators GCKR, GCK, GALK1 GCK 2/4885KCNH2 325/4885L3MBTL1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.